Session Type: Poster Session (Sunday)
Session Time: 9:00AM-11:00AM
Background/Purpose: Sarcopenia, the loss of skeletal muscle mass, is associated with adverse individual physical and metabolic changes contributing to morbidity and mortality. Sarcopenia is a core component of physical frailty that together impact negatively on an individual’s capability to live independently.
Sarcopenia and frailty are important problems among elderly individuals.
Although relationships between sarcopenia and various chronic inflammatory diseases have been shown, the role in rheumatologic disease is currently unknown. The aim of this study was to assess the prevalence of sarcopenia and frailty syndrome in patients with Rheumatoid arthritis (RA) and spondyloarthritis SpA).
Methods: Cross-sectional, observational and descriptive study in patients with RA and SpA (ACR and ASAS criteria) older than 50 years.
-Sarcopenia was defined as per the European Working Group on Sarcopenia in Older People definition as Skeletal muscle mass index (SMI) ≤ 8.87 kg/m2 in men and ≤ 6.42 kg/m2 in women. Body composition analysis was performed using bioelectrical impedance analysis (BIA): fat mass, fat-free mass and predicted skeletal muscle mass were collected. Skeletal muscle mass index (SMI) was calculated by appendicular skeletal muscle mass (sum of predicted muscle mass in all 4 limbs) divided by height squared.
– Fragility was measured according to the 5 criteria proposed by Fried, using the Frail scale, and it was considered fragile to the patient who met at least 3 and prefragiles to those who met at least 2.We applied the Frail Scale and registered data (demographic and diseased related data) using a cross-sectional, observational, and descriptive study design.
Frail scale: Based on five items, reflecting performance, selfreports and common co-morbidities (Morley JE et al., J Nutr Health Aging. 2012;16(7):601-8).
Did you feel worn out? or Did you feel tired?
Ability to climb one flight of stairs
Ability to walk 100 m
Self-report of >5% weight los
≤5 of: dementia; heart Disease; depression; arthritis; asthma;bronchitis/ emphysema; diabetes; hypertension; osteoporosis; stroke.
Results: 523 consecutive RA and SpA patients were included, 79.3 %) were female. Mean age was 55.4 years. Patients with spondyloarthritis were 39.3% ankylosing spondylitis, 31.6% psoriasis arthritis, 20.1% undifferentiated spondyloarthritis, 9% spondyloarthritis associated with inflammatory bowel disease.
Mean number of comorbidities was 1.47, with systemic hypertension and obesity as the most frequent ones (32.6 % and 27.1 %, respectively). Polypharmacy was found in 94.2 % and 63.9 % received more than five drugs simultaneously.
RA patients: 21.5 % met frailty criteria (42% in ≥ 65 years old patients). SpA patients:18.9% met frailty criterio (37% in ≥ 65 years old patients).
Conclusion: Prevalence of frailty in this study was high. Rheumatologists should make an early detection of signs of frailty.
The screenig and early detection of frailty can spur reforms to make routine care less hazardous, can focus on outcomes most relevant to patients and can aid in understanding effectiveness of health care interventions, including at the population level.
To cite this abstract in AMA style:Trujillo E, Aznar A, Sanchez H, Hernandez M, García A, Trujillo Martin M. Frailty and Sarcopenia in Inflammatory Rheumatic Disease [abstract]. Arthritis Rheumatol. 2019; 71 (suppl 10). https://acrabstracts.org/abstract/frailty-and-sarcopenia-in-inflammatory-rheumatic-disease/. Accessed June 6, 2020.
« Back to 2019 ACR/ARP Annual Meeting
ACR Meeting Abstracts - https://acrabstracts.org/abstract/frailty-and-sarcopenia-in-inflammatory-rheumatic-disease/